These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20175262)

  • 1. FDA drug information that never reaches clinicians.
    Collins C
    N Engl J Med; 2010 Feb; 362(6):561-2; author reply 563. PubMed ID: 20175262
    [No Abstract]   [Full Text] [Related]  

  • 2. Lost in transmission--FDA drug information that never reaches clinicians.
    Schwartz LM; Woloshin S
    N Engl J Med; 2009 Oct; 361(18):1717-20. PubMed ID: 19846841
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA drug information that never reaches clinicians.
    Messerli FH; Bangalore S
    N Engl J Med; 2010 Feb; 362(6):562; author reply 563. PubMed ID: 20175300
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA drug information that never reaches clinicians.
    Cook GE; Sasich LD; Sukkari SR
    N Engl J Med; 2010 Feb; 362(6):562-3; author reply 563. PubMed ID: 20175263
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA drug information that never reaches clinicians.
    Casoy J
    N Engl J Med; 2010 Feb; 362(6):561; author reply 563. PubMed ID: 20175299
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA drug information that never reaches clinicians.
    Hohneker J; Ericson S; Gruia G
    N Engl J Med; 2010 Feb; 362(6):561; author reply 563. PubMed ID: 20147728
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA eases medication guide distribution requirements.
    Traynor K
    Am J Health Syst Pharm; 2011 Apr; 68(8):649-50. PubMed ID: 21460167
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 11. A much-anticipated FDA reform bill is signed into law: progress and compromise.
    Nissen SE
    Curr Cardiol Rep; 2008 Feb; 10(1):1-2. PubMed ID: 18416992
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA approves once-daily efavirenz formulation, revised labeling.
    AIDS Treat News; 2002 Mar; (378):7. PubMed ID: 11965921
    [No Abstract]   [Full Text] [Related]  

  • 13. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997.
    Weeks EA
    Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459
    [No Abstract]   [Full Text] [Related]  

  • 14. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA prohibits extralabel use of two drug classes.
    J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA to require pediatric studies for drugs commonly used in children.
    Miller JL
    Am J Health Syst Pharm; 1999 Feb; 56(3):203. PubMed ID: 10030499
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA puts forth proposal to mandate patient information.
    Wechsler J
    Formulary; 1995 Oct; 30(10):622-3. PubMed ID: 10151725
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: Frequent utilization in the field of oncology.
    Yoshida K; Budha N; Jin JY
    Clin Pharmacol Ther; 2017 May; 101(5):597-602. PubMed ID: 28074611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.